Radiotracer firms launch MoAb agents

Two monoclonal-antibody-based radiopharmaceuticals that receivedFood and Drug Administration approval last year were launchedearly this month. Cytogen of Princeton, NJ, and marketing partnerC.R. Bard of Murray Hill, NJ, began selling their ProstaScintagent for detecting prostate cancer (SCAN 11/6/96), while Du PontMerck Radiopharmaceuticals of North Billerica, MA, began sellingVerluma, a small-cell lung cancer imaging agent developed by NeoRxof Seattle (SCAN 9/25/96).